We are in the Fourth Quarter so, Could begin at an
Post# of 30028
Amarantus anticipates launching LymPro in the fourth quarter of 2014 .
Amarantus plans to launch LymPro for RUO in the fourth quarter of 2014 , primarily targeting pharmaceutical clinical trials.
Amarantus anticipates completing enrollment of the 68 patient LP-002 extension in the fourth quarter and will announce data from an in-depth analysis from the full cohort of 140 subjects (72 patients + 68 patient extension) shortly thereafter .
full steam ahead
now tailor our initial marketing efforts towards the $150M RUO market , primarily targeting pharmaceutical companies engaged in Alzheimer's disease therapeutic trials.
We have nearly completed assembling the resources needed to launch LymPro to the RUO community in the fourth quarter
Thereafter , we intend to market LymPro to the broader medical community, initially under CLIA. We estimate the worldwide market for an Alzheimer's diagnostic is $3B
The company will make a final decision on which version of LymPro (Version 1 or Version 2) to launch under the CLIA designation, which will be marketed to the general population, following an in-depth analysis from the full cohort of 140 subjects.
The company anticipates launching LymPro under CLIA shortly after product launch in the RUO marketplace.
http://ir.stockpr.com/amarantus/company-news/...mpro-testr